Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the five brokerages that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $12.40.
A number of equities analysts have recently issued reports on the company. HC Wainwright reduced their price target on Inovio Pharmaceuticals from $5.00 to $3.00 and set a “neutral” rating on the stock in a research report on Monday. Oppenheimer decreased their price target on Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a research note on Monday, November 18th. JMP Securities reissued a “market outperform” rating and issued a $18.00 price target on shares of Inovio Pharmaceuticals in a report on Friday, January 10th. Finally, Royal Bank of Canada dropped their price target on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research note on Friday, November 15th.
Read Our Latest Report on Inovio Pharmaceuticals
Institutional Investors Weigh In On Inovio Pharmaceuticals
Inovio Pharmaceuticals Price Performance
Shares of INO stock opened at $1.87 on Friday. The stock’s 50-day moving average is $3.35 and its 200 day moving average is $6.05. Inovio Pharmaceuticals has a 1-year low of $1.74 and a 1-year high of $14.75. The company has a market cap of $48.81 million, a P/E ratio of -0.90 and a beta of 0.84.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Read More
- Five stocks we like better than Inovio Pharmaceuticals
- How to Calculate Stock Profit
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- The 3 Best Fintech Stocks to Buy Now
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.